TB-500 vs Thymosin Beta-4
Reviewed by the BestHealingPeptides Editorial Team ·
TB-500 is widely described as a fragment of thymosin beta-4, but in the research-chemical market the molecular identity supplied under the TB-500 label is not always defined. This comparison clarifies the relationship between the synthetic research peptide and the endogenous parent molecule, and discusses which to choose for a given research question.
TB-500
A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.
Thymosin Beta-4
A 43-amino-acid actin-sequestering peptide expressed in nearly all human cells. Distinct from the shorter TB-500 fragment; investigated in cardiac repair, corneal healing, neural regeneration, and dermal regeneration.
| Aspect | TB-500 | Thymosin Beta-4 |
|---|---|---|
| Sequence length | Synthetic fragment (vendor-dependent; commonly described as the LKKTETQ-containing region) | 43 amino acids (full-length Tβ4) |
| Molecular weight | ~889 Da (LKKTETQ heptapeptide) or as supplied | ~4.96 kDa |
| Identity confidence | Variable across suppliers — verify by mass spectrometry per batch | Defined recombinant or chemically synthesised 43-mer |
| Strongest evidence base | Tendon transection models, cell migration assays | Cardiac, corneal, full skin/dermal, tendon — broader literature |
| Cost (research-grade per mg) | Lower | Substantially higher |
| WADA category | S2 (peptide hormones / growth factors / mimetics) | S2 (same classification) |
Molecular identity
Thymosin beta-4 (Tβ4) is a 43-amino-acid 4.96 kDa endogenous protein, ubiquitously expressed and the principal G-actin sequestering protein in mammalian cells. 'TB-500' is the research-chemical-market label for a synthetic peptide commonly described as a fragment of Tβ4 incorporating the actin-binding 'LKKTETQ' motif, though the precise sequence supplied varies between vendors. Researchers should request a Certificate of Analysis confirming HPLC purity and mass-spectrometric sequence verification on every batch of TB-500 used in an in-vivo study — molecular-identity variability is the principal practical risk of the compound.
Evidence base — what each is studied for
Thymosin beta-4 has the larger and more methodologically robust evidence base, covering cardiac repair post-infarct (with dedicated Phase II clinical work), corneal wound healing (the original Sosne group findings), dermal wound healing, tendon and skeletal-muscle repair, and a broad role in actin dynamics. TB-500's published literature is smaller and often refers back to full-length Tβ4 studies for mechanistic claims; the fragment's own dedicated dataset focuses on tendon and cardiac models. Some studies marketed under the TB-500 label actually used full-length Tβ4 — readers should check the Methods sections of cited papers carefully.
Pharmacokinetics and route
Tβ4 is administered subcutaneously or intravenously in research; its plasma half-life is short (clearance within hours) but tissue distribution is broad. TB-500's reported plasma stability is similar but data are sparser for the specific fragment. Both are stable lyophilised and reconstituted with bacteriostatic water for research use. The shorter TB-500 sequence may favour rapid distribution into tissue versus the more retained Tβ4.
Cost and availability
Full-length Tβ4 is substantially more expensive than commercial TB-500 due to synthesis cost (a 43-residue peptide is materially more demanding than a shorter fragment). For research with no specific full-length-vs-fragment hypothesis, TB-500 is the cheaper practical choice; for research where the full-length actin-binding interface is needed, only Tβ4 will suffice.
Choosing between them
Use full-length thymosin beta-4 for research that targets the complete actin-binding interface, cardiac and corneal applications where the published evidence specifically used Tβ4, and any study where molecular-identity certainty is critical. Use TB-500 for cost-controlled tendon and skeletal-muscle research, but pre-register the sequence-verification step and treat the data as fragment-specific even where the underlying biology is shared.
Verdict
TB-500 and full-length thymosin beta-4 are mechanistically related but not interchangeable. For dedicated cardiac, corneal, and full actin-axis research, choose Tβ4. For tendon and exploratory work where cost matters and a verified fragment is acceptable, TB-500 is the practical default — but always verify the sequence on the supplied Certificate of Analysis.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.